Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00407329
Other study ID # uPAR
Secondary ID
Status Completed
Phase N/A
First received December 1, 2006
Last updated November 5, 2013
Start date November 2006
Est. completion date January 2012

Study information

Verified date November 2013
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Observational

Clinical Trial Summary

We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.


Description:

Histological inflammation in patients with Benign Prostatic Hyperplasia (BPH) appears to predict clinical progression and ultimate long-term response to various medical therapies, including finasteride. Discovery of a urine or serum marker of prostate inflammation will be an invaluable clinical tool to predict a man's risk of BPH progression and the efficacy of various medical therapies to reduce that risk.

Specific Aim:

We plan to determine if urokinase plasminogen activators (and/or other inflammatory markers) in serum, urine and tissue of patients can predict prostatic inflammation

Background:

Benign Prostatic Hyperplasia (BPH) and Inflammation

BPH is a common disorder of the prostate causing significant lower urinary tract symptoms and negatively affects the quality of life in a substantial proportion of men in North America. According to the National Institutes of Health (NIH), BPH affects more than 50% of men over age 60 and as many as 90% of men over the age of 70. Although there are numerous genetic and epigenetic changes associated with the progression of normal prostatic glandular formation to BPH, as early as 1994 our group suggested that the presence of prostatic inflammation could be associated with pathogenesis and progression of both histological and clinical BPH. We have demonstrated that histological prostate inflammation is very common in patients with BPH as well as patients who are both symptomatic and not symptomatic. Our local research group spearheaded an international consensus classification system for prostatic inflammation that we have subsequently employed in our ongoing study of over 8,000 men undergoing 3 serial biopsies over a 4 year period of time. The MTOPS BPH study data base subanalyses of the more than 1,000 men who underwent baseline biopsies strongly suggested that prostatic inflammation appears to be the strongest and most robust predictor of symptomatic progression as well as response to drug therapy. An analyses T-cell phenotypes, cytokine expression patterns and cellular cross talk in BPH tissues of 101 BPH patients and prostatic cell cultures showed that chronic inflammation triggers histological and clinical progression. The search for urine or serum biomarkers of prostatic inflammation is highly relevant to better target therapies for men with this common condition.

Urokinase Plasminogen Activator System

Proteolytic enzymes are required to mediate inflammatory cell infiltration in tissues, a process highly regulated by the cell surface-specific receptor (uPAR) a binding partner for the urokinase-type plasminogen activator (uPA). Numerous previous clinical investigations have indicated that serum levels of the plasminogen activation system are an effective marker of inflammation in several disease processes including CNS inflammation, asthma, metabolic syndrome and pre-eclampsia. Very little data is available regarding the plasma levels of soluble uPAR in benign prostatic diseases, although one previous report suggested higher average levels of soluble uPAR in patients with lower urinary tract symptoms. Theses authors reported a wide variation of uPAR in BPH patients with some having greatly elevated levels while others had undetectable levels. However, the author's did not have pathological confirmation of their findings and could not quantify the level of inflammation in the prostatic tissue. We hypothesize that the absolute or relative serum levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 2012
Est. primary completion date February 2008
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- scheduled for transurethral resection of the prostate

Exclusion Criteria:

- unable to give consent

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
transurethral resection of the prostate
resection of prostate

Locations

Country Name City State
Canada Centre for Advanced Urological Research Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

References & Publications (6)

McCabe NP, Angwafo FF 3rd, Zaher A, Selman SH, Kouinche A, Jankun J. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep. 2000 Jul-Aug;7(4):879-82. — View Citation

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387-98. — View Citation

Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999 Dec;84(9):976-81. — View Citation

Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001 Jun;87(9):797-805. Review. — View Citation

Nickel JC. Prostatic inflammation in benign prostatic hyperplasia - the third component? Can J Urol. 1994 Jan;1(1):1-4. — View Citation

Thompson IN, Goodman PJ, Tangen CM, Lucia MS, Miller CJ, Ford LC, et al. The influence of finsteride in the development of prostate cancer. New England Journal of Medicine, 2003; 349:211-220.

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02974751 - Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Terminated NCT04398966 - Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia N/A
Completed NCT04029012 - Penthrox in Rezūm BPH Phase 4
Recruiting NCT03912558 - Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients. N/A
Completed NCT00527488 - Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Phase 2
Recruiting NCT06323109 - US Imaging for the Assessment of LUTS
Completed NCT05628025 - Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
Completed NCT00256399 - Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) N/A
Terminated NCT03994263 - A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI N/A
Completed NCT03772808 - Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS) N/A
Completed NCT05818670 - Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study Phase 4
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Active, not recruiting NCT04198103 - Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia N/A
Completed NCT00696761 - The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Phase 4
Completed NCT00199550 - Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Phase 4
Completed NCT02702947 - Efficacy of Prunus Domestica Extract in BPH Phase 4
Completed NCT00154843 - A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Phase 2
Completed NCT00037141 - Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Phase 1/Phase 2
Recruiting NCT05620784 - Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP Phase 3
Not yet recruiting NCT05719220 - Effect of Group Preoperative Pelvic Floor Training for HoLEP